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Simple Summary: Breast cancer is the most diagnosed type of cancer worldwide and it has a high
survival rate. Thus, side effects related to breast cancer and treatments compromise lots of people’s
physical functions and health-related quality of life. For this reason, it is important to manage these
side effects in the follow up after treatments. The handgrip strength and the handgrip strength
relative to body mass index may constitute useful, simple, quick and economically feasible tools that
may help clinicians detecting these side effects, which is key to undertake actions for improving the
physical function and health-related quality of life of breast cancer survivors.
Abstract: Background: Although breast cancer (BC) is the most prevalent type of cancer in the world,
its high survival rate implies that many people live long after the treatments and face their side
effects. The physical function (PF) and health-related quality of life (HRQoL) of people surviving BC
decreases significantly, which makes important to identify markers that may be associated with a
better health status and prognosis. Previous studies suggest that handgrip strength (HGS) and HGS
relative to the body mass index (rHGS) are good indicators of PF and HRQoL in different populations.
However, it is unknown whether this applies to BC survivors. This study aimed to evaluate the
association of HGS and rHGS with PF and HRQoL in this population. Methods: Sixty female BC
survivors participated. Handgrip strength was assessed with a dynamometer. Arm volume was
estimated and upper limb impairments, as well as cancer-related fatigue, depression, life satisfaction
and HRQoL, were assessed using standardized questionnaires. Results: Higher levels of HGS and
rHGS were associated with higher levels of HRQoL, lower cancer-related fatigue, and fewer problems
with the affected arm. Conclusions: These results suggest that HGS may be a good indicator of
self-reported PF and HRQoL in female BC survivors.
Keywords: cancer; physical fitness; muscular strength; disability; life satisfaction; depression
1. Introduction
Breast cancer has the highest incidence worldwide with more than 2.2 million new
diagnoses in 2020 [1]. In Europe, there were 531,086 new diagnoses during 2020 [1].
According to the Spanish Association against Cancer (AECC) [2], 33,307 new cases were
diagnosed during 2019. Nevertheless, ongoing advances in early detection and treatment
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of breast cancer have led to a significant mortality reduction. Breast cancer is the type of
cancer with the highest survival rate following diagnosis, with 86% of patients surviving
after 5-year [3]. Such a high survival rate leads to more people living with the side
effects of the disease and its core treatments (chemotherapy, surgery, and radiotherapy) [4].
These side effects include the presence of lymphedema [5], cancer-related fatigue [6],
shoulder–arm disabilities [7,8], lower levels of cardiorespiratory fitness [9,10] and muscular
strength [11,12], sarcopenia [13], cardiac toxicity [14] or depression [15], among others. This
implies a considerable decrease in patients’ health-related quality of life (HRQoL) [16], and
could imply more difficulties to perform basic daily life tasks, such as dressing, combing
hair, working, shopping, exercising, etc.
Muscular strength is a powerful marker of present and future health in children [17],
adolescents [18,19], adults [20] and older adults [21]. In general population, higher levels
of muscle strength have shown to be related to a lower risk of developing cardiovascular
disease [22], type 2 diabetes [20], fragility [23] and mortality [24]. Specifically, handgrip
strength (HGS), and HGS relative to the body mass index (BMI), have been proposed
as highly relevant health indicators in different populations, such as young and older
adults [25], adult males [26], aging adults [27], women with systemic lupus erythemato-
sus [28], and women with fibromyalgia [29]. HGS and relative HGS (rHGS) have also
been proposed as a cardiometabolic risk predictor in children and adolescents [30] and
in middle-aged and older people [31,32], and as an all-cause [33–35] and cancer [36] mor-
tality predictor, allowing to obtain useful information from a simple, quick, and very
low-cost assessment.
The relationship of HGS with physical function and HRQoL in female breast cancer
survivors has been studied. Higher HGS was associated with less treatment-related disabil-
ity [37], less fear when using the affected limb in addition to less perceived weakness and
less pain in the affected arm [38], greater activity of the upper limbs [38], reduced presence
of depressive symptoms [39,40], higher self-reported HRQoL [41,42], less cancer-related
fatigue [43,44] and a more favorable body composition [45]. However, information on the
association of rHGS with health-related outcomes including HRQoL and cancer-associated
side effects is scarce in female breast cancer survivors. RHGS is a good indicator of general
health in different populations. For instance, higher levels of rHGS are associated with
greater mobility in older adults [46,47], better cardiovascular health in obese women [48],
lower prevalence of metabolic syndrome in adults [49], lower prevalence of osteoporosis in
women [50], lower cardiometabolic risk in women with systemic lupus erythematosus [28],
and lower risk of depressive mood in women [39]. Therefore, we speculated that higher
rHGS would be related to better self-reported physical function and HRQoL in female
breast cancer survivors.
Consequently, the aim of this study was to assess the association of HGS and rHGS
with physical function and HRQoL in female breast cancer survivors. Additionally, the
secondary aim was to explore if the association of HGS and rHGS of the affected and
nonaffected arm with all the outcomes differed.
2. Materials and Methods
2.1. Design
A cross-sectional study was conducted with the baseline values of the EFICAN (Ejerci-
cio FÍsico para pacientes con CÁNcer de mama) clinical trial [51].
2.2. Participants
Sixty women voluntarily participated in this study. They were recruited through
different cancer-related associations and through announcements on social networks,
press and radio in the city of Almería. The inclusion criteria were to be a breast cancer
survivor and to have completed the core treatments of the disease (consisting of adjuvant
chemotherapy, surgery and/or radiotherapy) in the 10 years prior to the beginning of the
study. The exclusion criteria were the existence of pulmonary or cardiovascular disease,
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having metastatic breast cancer, planning a breast reconstruction intervention within
3 months of the beginning of the study and regularly performing >300 min per week
of structured exercise. The study protocol was approved by the Ethics Committee of
the Hospital Universitario Torrecárdenas de Almería, Spain (ref: Ejercicio-CáncerUAL
[98/2019]). In addition, all the participants were duly informed and signed the informed
consent form prior to being included in the study.
2.3. Protocol
Women interested in participating in the study filled out an online questionnaire ask-
ing for information about their disease and treatment. Participants who met the inclusion
criteria underwent a medical evaluation to confirm that they met the study participation
criteria. After obtaining medical authorization to participate in the study, the participants
underwent a physical assessment at the University of Almería facilities. These assessments
began by completing a series of questionnaires related to different quality of life variables.
Then, the presence of lymphedema and handgrip strength were assessed.
2.4. Assessments
2.4.1. Handgrip Strength
Handgrip strength was assessed using a digital dynamometer (TKK 5401 Grip-D,
Takei Scientific Instruments Co. Ltd., Niigata, Japan), which has been used in previous
studies on female breast cancer survivors [38,52–54]. Two attempts were made, alternating
each hand, and the best result from each was selected. The mean value obtained was taken
as the total score [55].
Handgrip strength relative to BMI was defined as HGS divided by BMI [46].
2.4.2. Shoulder–Arm Disabilities
To assess shoulder–arm disabilities, we studied the arm volume (which is related to
lymphedema) and the participants’ disability or difficulty in the upper limbs.
The arm volume was assessed by estimating the volume of each arm using the trun-









C2i + CiCi−1 + Ci−1
2
)
where n = number of segments, L = length of each segment, and Ci and Ci−1 = circumference
at each end of the segment.
For this, the arm’s perimeter was measured at 6 different points (with 6 cm of sepa-
ration between them) depending on the length of each participant’s arms following the
protocol by Sander et al. [56] The difference of volume between arms were computed.
Upper-limb disability or difficulty was assessed using the Spanish version [57] of the
Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire [37] with one optional
additional module, intended to measure the extent of the injury to the upper limb when
working. The final score ranged 0 to 100, where a higher number indicated greater disability
or difficulties.
2.4.3. Cancer-Related Fatigue
Cancer-related fatigue was measured using the Spanish version [58] of the Functional
Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire [59]. The scores range from
0 to 52, where a higher score indicates lower fatigue.
2.4.4. Depression
Depressive symptoms were assessed using the Spanish version [60] of the 20-item
Center for Epidemiologic Studies-Depression Scale (CES-D) questionnaire [61]. The final
score ranges from 0 to 60. A higher the total score means greater depressive symptoms.
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2.4.5. Life Satisfaction
Life satisfaction was assessed through the Satisfaction With Life Scale (SWLS) question-
naire [62], using its Spanish version [63], which has been validated for cancer patients [64].
The final score ranges from 0 to 25, where a greater score indicates greater satisfaction
with life.
2.4.6. Health-Related Quality of Life
HRQoL was assessed using the European Organization for Research and Treatment
of Cancer, Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) [65] in its Spanish
version [66], with its complementary module for breast cancer European Organization for
Research and Treatment of Breast Cancer, Cancer-Specific Quality-of-Life Questionnaire
Module (EORTC QLQ-BR23) [67], also in its Spanish version [68]. Each of the subscale has
a total score of 1–100, obtained as explained elsewhere [69], a higher score means a higher
response level.
2.5. Statistical Analysis
Descriptive characteristics are presented in Table 1, using the mean and standard
deviation for quantitative variables, and the number and frequency for categorical variables.
The normality of the main variables was studied using histograms, Q-Q plots and through
the Kolmogorov–Smirnov test. The association of HGS and rHGS with the aforementioned
outcome variables was analyzed through partial correlation, adjusting for age, BMI and
time since the disease diagnosis, to control for potential confounding. Finally, a linear
regression analysis was performed including the variables related to physical function and
quality of life as dependent variables in separate models, and the HGS as the independent
variable, using the same adjustment variables. Homoscedasticity and linearity assumptions
of the linear regression models, as well as the normality, no-multicollinearity and no-
autocorrelation of the residuals were checked. In addition, the detection of possible outliers
was studied through boxplots. Additional exploratory analyses were carried out to assess
the potential differential association of the absolute and rHGS of the affected and non-
affected with the above outcomes. All analyses were carried out using SPSS software
(IBM SPSS Statistics for Windows, Version 27.0, IBM Corp., Armonk, New York, NY, USA).
Statistical significance was set at p < 0.05.
Table 1. Descriptive characteristics of the study participants.
Variable n Median Mean SD Minimum Maximum
Age (years) 60 53.2 52.3 9.0 28.8 70.2
Height (cm) 60 160.0 160.1 5.5 149.5 172.9
Weight (kg) 60 67.4 68.7 11.5 46.7 103.0
BMI (kg/m2) 60 26.4 26.9 4.7 18.7 40.0
Time since diagnosis (years) 60 4.0 4.5 3.1 0.0 11.0
HGS (kg) 60 25.9 25.9 5.4 13.1 34.2
rHGS (kg) 60 1.9 2.0 0.6 0.7 3.5
Arm volume difference a (%) 60 0.9 1.8 6.4 −12.3 29.1
DASH (range 0–100) 60 12.9 18.0 16.4 0.0 65.8
DASH work (range 0–100) 58 0.0 17.6 25.6 0.0 100.0
FACTI–F (range 0–52) 60 41.0 38.5 8.9 18.0 52.0
CES–D (range 0–60) 60 13.5 15.4 10.7 0.0 49.0
SWLS (range 0–25) 60 18.5 18.3 3.6 9.0 25.0
EORTC QLQ-C30
QL2 subscale (range 0–100) 60 75.0 72.0 17.5 16.7 100.0
PF2 subscale (range 0–100) 60 93.3 86.9 14.3 33.3 100.0
RF2 subscale (range 0–100) 60 100.0 86.2 20.1 16.7 100.0
EF subscale (range 0–100) 60 75.0 75.0 23.8 0.0 100.0
CF subscale (range 0–100) 60 83.3 76.2 26.5 0.0 100.0
SF subscale (range 0–100) 60 83.3 71.5 33.3 0.0 100.0
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Table 1. Cont.
Variable n Median Mean SD Minimum Maximum
FA subscale (range 0–100) 60 33.3 29.0 23.3 0.0 100.0
NV subscale (range 0–100) 60 0.0 0.6 3.0 0.0 16.7
PA subscale (range 0–100) 60 16.7 20.1 23.1 0.0 83.3
DY subscale (range 0–100) 60 0.0 12.4 18.5 0.0 66.7
SL subscale (range 0–100) 60 33.3 38.4 30.2 0.0 100.0
AP subscale (range 0–100) 60 0.0 4.0 10.9 0.0 33.3
CO subscale (range 0–100) 60 0.0 15.3 22.6 0.0 100.0
DI subscale (range 0–100) 60 0.0 2.8 9.4 0.0 33.3
FI subscale (range 0–100) 60 0.0 18.1 27.2 0.0 100.0
EORTC QLQ-BR23
ST subscale (range 0–100) 60 21.4 21.8 17.0 0.0 71.4
AS subscale (range 0–100) 60 11.1 16.9 20.2 0.0 100.0
BS subscale (range 0–100) 60 8.3 18.1 19.4 0.0 100.0
BI subscale (range 0–100) 60 83.3 73.5 28.9 0.0 100.0
FU subscale (range 0–100) 60 66.7 52.8 32.6 0.0 100.0











Treatment (n = 60)
Chemotherapy 46 76.7
Radiotherapy 52 86.7
Surgical procedure (n = 60)
Tumerectomy 41 68.3
Mastectomy 18 30.0
No surgery 1 1.7
Lymph node resection (n = 60) 25 41.7








SD, standard deviation; HGS, handgrip strength; rHGS, relative handgrip strength; DASH, Disabilities of the Arm, Shoulder and Hand
questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; CES-D, Center for Epidemiologic Studies Depression
Scale; SWLS, Satisfaction with life scale; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer; QL2, global
health status/quality of life; PF2, physical function; RF2, task performance; EF, emotional performance; CF, cognitive performance; SF,
social performance; FA, fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnea; SL, insomnia; AP, loss of appetite; CO, constipation; DI,
diarrhea; FI, financial difficulties; EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer module;
ST, side effects of therapy; AS, arm symptoms/discomfort; BS, breast symptoms/discomfort; BI, body image; FU, future perspective; SEF,
sexual performance; RH, hormone receptor; HER2, HER2 protein; BSGC, selective sentinel lymph node biopsy. a Difference between the
volume of the right and left arm (expressed in %).
3. Results
The descriptive characteristics of the study participants are presented in Table 1. Sixty
female breast cancer survivors with an average age of 52.3 years (standard deviation [SD]
9.0) participated in this study. A total of two women were unable to complete the body
composition assessments using bioimpedance because of heart problems (the presence of
pacemakers) and feet problems. The average time since diagnosis was 4.5 (SD 3.1) years,
with a maximum of 11 years since diagnosis, and the average HGS was 25.9 (SD 5.4) kg.
Table 2 shows the association between HGS and rHGS to arms volume difference
and self-reported shoulder–arm disabilities, fatigue, depressive symptoms, life satisfaction
and HRQoL, adjusting for the participants’ age, BMI and time since diagnosis. A negative
association was found between HGS and rHGS to shoulder–arm disabilities (assessed
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using both the DASH questionnaire and the arm symptoms/discomfort subscale of the
EORTC QLQ-BR23 module). Additionally, a positive association between HGS and rHGS
to global health status/quality of life subscale of the EORTC QLQ-C30 questionnaire was
found. Furthermore, a significant negative association was found between HGS and rHGS
to fatigue (assessed using both FACIT-F questionnaire and the fatigue subscale of the
EORTC QLQ-C30 questionnaire). There was no association of absolute or relative HGS
with depressive symptoms, life satisfaction or any other quality of life subscale of the
EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires (all p > 0.05).
Table 2. Partial correlation assessing the association of HGS, and rHGS with arms volume difference, shoulder–arm
disabilities, fatigue, depressive symptoms, life satisfaction and self-reported HRQoL in female breast cancer survivors.
HGS rHGS
Variable n r p r p
Arms volume
difference a 60 −0.103 0.447 −0.073 0.589
DASH 60 −0.210 0.123 −0.418 0.001
DASH work module 58 −0.284 0.035 −0.361 0.006
FACIT-F 60 0.401 0.002 0.493 <0.001
CES-D 60 −0.122 0.376 −0.186 0.161
SWLS 60 0.069 0.617 0.099 0.459
EORTC QLQ-C30
QL2 subscale 60 0.289 0.030 0.387 0.003
PF2 subscale 60 0.103 0.448 0.254 0.054
RF2 subscale 60 0.111 0.410 0.182 0.172
EF subscale 60 0.211 0.115 0.179 0.179
CF subscale 60 0.148 0.270 0.165 0.216
SF subscale 60 −0.093 0.491 0.188 0.157
FA subscale 60 −0.164 0.224 −0.274 0.038
NV subscale 60 −0.041 0.764 0.121 0.365
PA subscale 60 −0.152 0.258 −0.165 0.216
DY subscale 60 −0.005 0.972 −0.052 0.698
SL subscale 60 −0.030 0.826 −0.076 0.572
AP subscale 60 −0.246 0.065 −0.100 0.457
CO subscale 60 −0.100 0.458 0.023 0.862
DI subscale 60 0.014 0.920 0.067 0.619
FI subscale 60 0.167 0.215 −0.085 0.524
EORTC QLQ-BR23
ST subscale 60 −0.139 0.304 −0.140 0.294
AS subscale 60 −0.346 0.008 −0.332 0.011
BS subscale 60 −0.025 0.856 −0.108 0.421
BI subscale 60 0.089 0.510 0.238 0.072
FU subscale 60 0.153 0.256 0.120 0.370
SEF subscale 60 0.078 0.565 0.197 0.138
r, partial correlation coefficient; p, p-value; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; FACIT-F, Functional
Assessment of Chronic Illness Therapy-Fatigue; CES-D, Center for Epidemiologic Studies Depression Scale; SWLS, Satisfaction with life
scale; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer; QL2, global health status/quality of life; PF2,
physical function; RF2, task performance; EF, emotional performance; CF, cognitive performance; SF, social performance; FA, fatigue; NV,
nausea and vomiting; PA, pain; DY, dyspnea; SL, insomnia; AP, loss of appetite; CO, constipation; DI, diarrhea; FI, financial difficulties;
EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer module; ST, side effects of therapy;
AS, arm symptoms/discomfort; BS, breast symptoms/discomfort; BI, body image; FU, future perspective; SEF, sexual performance. The
analyses were adjusted for age, BMI, and time since diagnosis. a Difference between the volume of the right and left arm (expressed in %).
Table 3 shows the results of the linear regression analysis assessing the association
between HGS and rHGS to the variables that were previously significant in the partial
correlation analysis, controlling for the potential confounding effects of age, BMI and time
elapsed since diagnosis. As examples, an additional kg in the HGS test was associated with
0.653 (95% CI 0.262 to 1.044; ß = 0.397; p = 0.001) more units on the cancer-related fatigue
scale, or with 1.114 (CI 95 % 0.115 to 2.113; ß = 0.289; p = 0.030) more units on the global
health status/quality of life subscale of the EORTC QLQ-C30 questionnaire. Along the
same lines, an additional kg of rHGS was associated with 12.589 (95% CI −19.914 to −5.265;
ß = −0.445; p = 0.001) units less on the disabilities of the arm, shoulder and hand scale,
with 7.911 (95% CI 4.176 to 11.645; ß = 0.515; p < 0.001) more units on the cancer-related
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fatigue scale, or with 14.650 (95% CI 5.296 to 24.003; ß = 0.408; p = 0.003) units on the global
health status/quality of life subscale of the EORTC QLQ-C30 questionnaire.
Table 3. Linear regression analysis assessing the association between HGS and rHGS to shoulder–arm disabilities, fatigue
and HRQoL, controlling for the potential confounding effects of age, BMI and time elapsed since diagnosis.
HGS rHGS
Variable β B SD 95% CI p β B SD 95% CI p
Weight −0.040 −0.085 0.290 −0.666, 0.496 0.771 −0.591 −11.722 2.301 −16.331, −7.112 <0.001
DASH −0.244 −0.740 0.382 −1.507, 0.026 0.058 −0.445 −12.589 3.656 −19.914, −5.265 0.001
DASH work module −0.278 −1.311 0.607 −2.529, −0.093 0.035 −0.374 −16.349 5.750 −27.878, −4.821 0.006
FACIT-F 0.397 0.653 0.195 0.262, 1.044 0.001 0.515 7.911 1.864 4.176, 11.645 <0.001
EORC QLQ-C30
QL2 subscale 0.289 1.114 0.499 0.115, 2.113 0.030 0.408 14.650 4.669 5.296, 24.003 0.003
FA subscale −0.225 −0.967 0.552 −2.074, 0.140 0.085 −0.382 −15.407 5.243 −25.913, −4.900 0.005
EORTC QLQ-BR23
AS subscale −0.347 −1.300 0.476 −2.253, −0.346 0.008 −0.343 −11.993 4.546 −21.100, −2.886 0.011
β, standardized regression coefficient; B, non-standardized regression coefficient; SD, standard deviation; CI, confidence interval; p, p-value;
BMI, body mass index; HGS, hand grip strength; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; FACIT-F, Functional
Assessment of Chronic Illness Therapy-Fatigue; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer; QL2,
global health status/quality of life; EORTC QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer
module; AS, arm symptoms/discomfort. The analyses were adjusted for age, BMI (body mass index) and time since diagnosis, except for
the body composition variables, where BMI was excluded as the adjustment variable.
The exploratory analyses assessing the specific associations of HGS and rHGS, dif-
ferentially assessed with the affected and nonaffected arms, with all the outcomes are
presented in Appendix A (Table A1). Overall, the association of the absolute and relative
HGS of both arms showed a similar association with the outcomes.
4. Discussion
The main findings of the present study suggest that a higher absolute HGS is associated
with fewer shoulder–arm disability, less cancer-related fatigue and greater HRQoL in female
breast cancer survivors. Furthermore, a higher rHGS is significantly associated with less
shoulder-arm disabilities, less cancer-related fatigue and higher HRQoL. These results
suggest that both absolute and relative HGS may be good indicators of the health status
of breast cancer survivors in the follow-up after core treatments. Particularly, the rHGS
revealed relatively stronger associations with the studied outcomes.
No association of HGS, or rHGS with arms volume difference was observed. However,
the present study observed a negative association of HGS and rHGS with shoulder–arm
impairments. In this line, other studies [38,70], observed that higher HGS was associated
with lower upper limb disability. Additionally, Lee et al. [38]. observed a negative associa-
tion of HGS with subjective weakness of the affected arm, fear of using the affected arm,
and recommendations from the medical professional to restrict the use of the affected arm
and with limited activity in the affected arm. Future research should elucidate if upper
limb impairments and limited physical activity might be associated to medical recommen-
dations, which would highlight the great influence of medical support in the follow-up
after completing breast cancer treatments, specifically, on shoulder–arm disability.
The negative associations observed between HGS and rHGS with cancer-related
fatigue, support the findings obtained by Kalter et al. [43]., Kneis et al. [44]., and Cantarero-
Villanueva et al. [52]. who observed that higher HGS was associated with lower cancer-
related fatigue. Fatigue is one of the main side effects related to breast cancer treatments [6]
and its significant increase during and after treatments cause a decrease in the patients’
quality of life, as well as in their ability to carry out daily life activities [71]. Then, con-
sidering the impact that fatigue may have on breast cancer survivors’ lives, assessing its
presence becomes of major importance and absolute and relative HGS test may be very
useful tools.
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Despite what has been indicated in the previous literature [39,40,42,52], no association
was observed between HGS, or rHGS, with depressive symptoms. This may be due to the
use of different assessment instruments.
It has been shown that HRQoL is reduced after breast cancer core treatments [16].
The results presented in this study suggest that higher HGS and rHGS are associated with
higher self-reported quality of life. These results are in line with those of Kaya et al. [41].
and Paek and Choi [42], who observed that lower HGS was associated with lower HRQoL,
in spite of using different HRQoL scales. Further prospective research is needed to elucidate
whether absolute or relative HGS might be associated with a lower decrease of HRQoL
in the follow-up (e.g., 10 years as the context of this study) after completing the core
treatments for breast cancer.
It should be noted that additional exploratory analyses were carried out to determine
if HGS or rHGS of the affected and nonaffected arms could show stronger associations with
the different self-reported physical function and quality of life studied outcomes, but the
observed results were similar to previous analyses. Other studies analyzed the association
of HGS of the affected arm [40,44,52] and HGS of the dominant hand [43,53] with physical
function and HRQoL outcomes but any of them explored if using HGS of the affected and
nonaffected arm or both could show stronger associations.
The handgrip strength test is a quick, simple and economically feasible assessment
that may help clinicians initiate a process to identify the presence of shoulder–arm dis-
abilities and cancer-related fatigue, as well as a decrease of quality of life in breast cancer
survivors, which constitute three of the main side effects during and after cancer treatments.
The detection of these side effects could lead to the implementation of actions for their
improvement, causing a significant improvement on these patients’ well-being.
To the best of our knowledge, the present study is the first to examine the association of
rHGS with different self-reported physical function and quality of life outcomes. According
to these results, rHGS shows relatively stronger associations than HGS with all the analyzed
outcomes. Consequently, rHGS could be speculated to be a better potential predictor of
physical function and HRQoL.
This study also included standardized assessment instruments for this population,
which has shown relevant associations that may contribute to the inclusion of HGS as-
sessment in clinical practice, facilitating the early detection of breast cancer treatments
side effects, and their improvement. However, further prospective research is needed to
evaluate the utility of implementing the handgrip strength test in clinical practice to predict
the deterioration of function and patient-reported outcomes following treatments.
This study has limitations that must be highlighted. The cross-sectional design pre-
cludes the establishment of causal relationships. The sample size was relatively low and
studies with larger samples are needed to confirm or contrast these findings. Additionally,
women included in the study had undergone breast cancer surgery and finished the core
treatments up to 10 years before enrolment, which might result in a rather heterogeneous
sample. Finally, we lacked information on the history of hormone therapy, which could
affect muscle quality and strength.
5. Conclusions
In conclusion, the results of the present study suggest that both HGS and, particularly,
rHGS could be good indicators of shoulder–arm disabilities, fatigue and decreased quality
of life in breast cancer survivors.
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Appendix A
Table A1. Partial correlation assessing the association of HGS, and rHGS of the affected and nonaffected arms with arms
volume difference, shoulder–arm disabilities, fatigue, depressive symptoms, life satisfaction and self-reported HRQoL in
female survivors of breast cancer.
Variable
Affected Arm Nonaffected Arm
HGS rHGS HGS rHGS
n r p r p r p r p
Arms volume difference a 60 −0.083 0.554 −0.069 0.621 −0.107 0.444 −0.099 0.477
DASH 60 −0.255 0.066 −0.437 0.001 −0.127 0.363 −0.339 0.012
DASH work module 58 −0.346 0.011 −0.433 0.001 −0.211 0.129 −0.331 0.015
FACIT-F 60 0.373 0.006 0.490 <0.001 0.433 0.001 0.527 <0.001
CES-D 60 −0.069 0.622 −0.135 0.329 −0.137 0.330 −0.198 0.152
SWLS 60 −0.040 0.775 0.023 0.870 0.142 0.310 0.158 0.253
EORTC QLQ-C30
QL2 subscale 60 0.188 0.177 0.319 0.019 0.267 0.053 0.387 0.004
PF2 subscale 60 0.085 0.546 0.332 0.014 0.076 0.590 0.320 0.018
RF2 subscale 60 0.132 0.347 0.306 0.024 −0.020 0.889 0.196 0.156
EF subscale 60 0.228 0.101 0.220 0.110 0.247 0.075 0.236 0.086
CF subscale 60 0.151 0.282 0.193 0.163 0.119 0.398 0.185 0.181
SF subscale 60 −0.134 0.338 0.215 0.119 −0.105 0.454 0.236 0.085
FA subscale 60 −0.131 0.352 −0.332 0.014 −0.150 0.284 −0.341 0.011
NV subscale 60 −0.169 0.227 −0.017 0.902 −0.186 0.181 −0.115 0.406
PA subscale 60 −0.105 0.454 −0.220 0.109 −0.039 0.780 −0.176 0.202
DY subscale 60 0.010 0.943 −0.108 0.437 0.070 0.616 −0.064 0.646
SL subscale 60 −0.041 0.768 −0.112 0.422 0.031 0.826 −0.077 0.582
AP subscale 60 −0.360 0.008 −0.311 0.022 −0.157 0.262 −0.171 0.216
CO subscale 60 −0.045 0.747 0.040 0.772 −0.073 0.604 0.022 0.876
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Variable
Affected Arm Nonaffected Arm
HGS rHGS HGS rHGS
n r p r p r p r p
DI subscale 60 −0.018 0.897 0.008 0.954 −0.123 0.381 −0.079 0.569
FI subscale 60 0.115 0.411 −0.157 0.256 0.171 0.222 −0.124 0.372
EORTC QLQ-BR23
ST subscale 60 −0.159 0.255 −0.181 0.191 −0.076 0.591 −0.133 0.337
AS subscale 60 −0.344 0.012 −0.339 0.012 −0.229 0.099 −0.249 0.070
BS subscale 60 −0.002 0.990 −0.097 0.487 0.039 0.779 −0.060 0.664
BI subscale 60 0.069 0.625 0.241 0.079 0.193 0.167 0.326 0.016
FU subscale 60 0.207 0.137 0.139 0.316 0.045 0.750 0.024 0.864
SEF subscale 60 0.012 0.934 0.162 0.242 0.095 0.497 0.208 0.130
r, correlation coefficient; p, p-value; DASH, Disabilities of the Arm, Shoulder and Hand questionnaire; FACIT-F, Functional Assessment of
Chronic Illness Therapy-Fatigue; CES-D, Center for Epidemiologic Studies Depression Scale; SWLS, Satisfaction with life scale; EORTC
QLQ-C30, European Organization for Research and Treatment of Cancer; QL2, global health status/quality of life; PF2, physical function;
RF2, task performance; EF, emotional performance; CF, cognitive performance; SF, social performance; FA, fatigue; NV, nausea and
vomiting; PA, pain; DY, dyspnea; SL, insomnia; AP, loss of appetite; CO, constipation; DI, diarrhea; FI, financial difficulties; EORTC
QLQ-BR23, European Organization for Research and Treatment of Cancer—breast cancer module; ST, side effects of therapy; AS, arm
symptoms/discomfort; BS, breast symptoms/discomfort; BI, body image; FU, future perspective; SEF, sexual performance. The analyses
were adjusted for age, BMI, and time since diagnosis. a Difference between the volume of the right and left arm (expressed in %).
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